Route 92 Medical Lands $50 Million to Scale its Stroke-Tech Commercial Push From West Jordan

The $50 million funding round comes just weeks after Route 92 Medical moved its headquarters to West Jordan from San Mateo, California

14 April 2026 — West Jordan, Utah — Route 92 Medical has landed a new $50 million round of growth funding as the West Jordan-based MedTech company pushes to accelerate commercial adoption of its stroke-treatment platform, expand internationally, and keep building clinical evidence behind its neurovascular products.

According to the company news release, the funding round was led by Novo Holdings, with returning investors (U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners, and The Vertical Group) plus new investor, Sectoral Asset Management, also joining the round.

This latest financing brings total funding for 11-year-old Route 92 to ~$275 million.

That said, it represents the first financing for the medical device company since it relocated its headquarters to Utah earlier this year, a fact made clear in March when the Utah Governor’s Office of Economic Opportunity announced a post-performance tax credit for Route 92, as a Utah-based company. {This presumes the firm is successful in its plans to add 116 new high-paying jobs and invest $5.067 million in Salt Lake County over the next five years.}

As Founder/CEO Tony Chou said:

"We’ve seen rapid growth in the adoption of our products over the past year ... (and) we’re on a mission to improve outcomes for patients suffering from acute ischemic stroke...."

Route 92's Quiet Three-year Presence in Utah

To be clear, Route 92 has had a presence in Utah since November 2022 when it announced a new 40,000-square-foot manufacturing site in Salt Lake City and said the facility would "... substantially augment its manufacturing capabilities while serving as a clinician training and education center."

At the time, Chou noted that

"Having a second home base (in Salt Lake City) for attracting additional talent is all in support of our long-term growth strategy."

Since then, Route 92 has hit several significant milestones, including

• A November 2023 oversubscribed Series F financing of more than $31 million, and
• A September 2024 "extension" of its Series F funding of $50 million.

{NOTE: Consider the first $31 million an F-1 funding, and the additional $50 million an F-2 funding.}

Then, nearly midway between the F-1 and F-2 funding rounds, Route 92 announced in April 2024 that it had received "510(k) clearance for the FreeClimb 54 reperfusion system (from the U.S. Food and Drug Administration, a system), comprised of (its) FreeClimb 54 aspiration catheter paired with (its) Tenzing 5 delivery catheter."

Route 92 Medical's Role in MedTech and Why it Matters

So what exactly does Route 92 Medical do?

In company-speak, the firm makes catheter-based systems used by neurointerventional specialists (aka, brain surgeons) to treat acute ischemic stroke.

These surgeons thread devices through patient blood vessels to reach a clot in the brain and remove it quickly enough to restore blood flow, typically clots that cause such strokes, or in some instances, clots that are caused during a stroke.

As the company explained in its November 2022 news release announcing the opening of its facility in Salt Lake City,

"(Around the globe) ... strokes affect about 16 million people and kill an estimated 6 (annually)."

That release went on to explain that

"In the United States, more than 800,000 patients suffer from acute ischemic stroke each year, with an annual healthcare cost of $104 billion. Stroke is a critically time-sensitive disease and without appropriate diagnosis and treatment, most patients suffer permanent disability or death.

"Despite recent advances in life-saving endovascular treatment, only approximately 10 percent of eligible stroke patients are treated endovascularly today."

That is why the phrase “neurovascular intervention” in this most recent news release, and on Route 92's website, matters so much.

This is not abstract medical branding.

It is the business of helping physicians reach and remove stroke-causing blood clots more quickly, completely, and efficiently.

With its growing portfolio of FDA-cleared neurological devices, Route 92 Medical’s commercial focus sits in one of the most consequential corners of device medicine, one where

• Procedure time,
• First-pass performance, and
• Ease of use can directly shape both
  — Clinical outcomes, and
  — Product adoption.

In this regard, the new $50 million in funding is not surprising at all.

And the Route 92 capital stack clearly suggests what investors are funding now.

Clearly, this is no longer just an early-stage concept company.

Rather, it's a company that has built manufacturing capacity, developed a clearer Utah operating base, and is now raising growth money to push broader commercial penetration.

In other words, this is an obvious bet that ...

the Route 92 combination of product differentiation, clinician adoption, and expanding commercial infrastructure can turn a promising stroke-intervention platform into a larger neurovascular franchise.

Taken from the perspective of Kelvyn Cullimore, CEO of BioUtah, the nonprofit life sciences association of the state,

“Route 92 is another great example of the innovative nature of the life sciences in Utah. Their advanced neurointervention systems will save lives the world over.”

What this Means for Utah, Route 92 Medical, and the State's Life Sciences Industry

From a Utah Money Watch perspective, the real story is a combination of both the sequence and the signal.

Route 92 Medical did not simply raise money.

After starting and running a good race in Silicon Valley, it

• Built in Utah,
• Expanded in Utah,
• Shifted its headquarters to Utah, and then
• Raised another $50 million to help it scale ... in Utah.

To be clear, Route 92 is maintaining operations in Utah.

But it's also not the only life sciences firm to move its HQ to Utah.

Case in point (as noted in the mid-March 2026 Utah Money Watch story about the $550 million acquisition of West Valley City-based firm, Scientia Vascular), don't forget that Scientia launched outside of Utah some five-and-a-half-years BEFORE moving to the state in June 2013.

Then, nearly 14 years AFTER moving to Utah, Scientia announced it was getting gobbled-up by Medtronic after achieving great success within the state.

Such a long-view perspective is part of what makes Route 92 worth watching now that its HQ is here, along with all of the other life sciences firms also based in the state, whether grown organically or by transplantation.

In that regard, this story then is not just about a firm getting funding, although that is the "news hook."

More critically, the crux of this writeup is the fact that Utah has become central to where Route 92 Medical will manufacture, innovate, hire, and grow.

That, obviously, is an interesting development and one to be aware of both today and into the future.

Publisher's Note

This writeup was originally published and distributed to our Subscribers at approximately 06:45am MT on Wednesday, 15 April 2026.

However, if this report/article came to your attention sometime after this date/time and you'd like to change that, then (to become a subscriber), please 

1. Click on a "Subscribe" button on any Utah Money Watch webpage (visit www.UtahMoneyWatch.com),
2. Enter in your name in the proper field in the popup window that appears on-screen, and
3. Enter your preferred email address in the proper field too.

That's it. Thanks.

Team Utah Money Watch